Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- RMAT and Fast Track designations follow CB-010's durable complete responses  at dose level 1 in the ANTLER Phase 1 trial -- -- CB-010 is the 1 st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout --

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

-- CaMMouflage Phase 1 clinical trial to initiate patient enrollment at dose level 1 in early 2023 -- -- CB-011 is engineered with a differentiated immune cloaking strategy, designed to enhance persistence --

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 --

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Ongoing complete response at 15 months reported in first patient treated with CB-010 Ongoing complete response at 15 months reported in first patient treated with CB-010

Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022

iShares Core U.S. Aggregate Bond ETF

iShares iBoxx High Yield Corporate Bond ETF

iShares Core S&P 500 ETF

iShares Russell 1000 ETF

iShares iBoxx $ Investment Grade Corporate Bond ETF

iShares National Muni Bond ETF

Invesco QQQ

Vanguard FTSE Developed Markets ETF

Vanguard S&P 500 ETF

Vanguard Tax-Exempt Bond Index ETF

Trading activity on the Tradeweb European ETF marketplace amounted to EUR 49.7 billion in September. Total consolidated U.S. ETF notional value traded in September 2022 reached USD 51 billion.

Tradeweb Exchange-Traded Funds Update - September 2022

Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable.

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Caribou Biosciences is the biotech behind some cutting-edge cancer therapies

This Biotech Stock Could Offer Big Growth – Even During A Recession

-- 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial -- -- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial --

Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Adicet Bio, Inc.

IVERIC bio Inc

Chinook Therapeutics

Kura Oncology

 Pliant Therapeutics

Rocket Pharma

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

7 Cheap Biotech Stocks to Buy Now

Proof of concept established using CRISPR allogeneic CAR-T CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma. Additional results from the phase 1 ANTLER study using CB-010 for the treatment of patients with relapsed/refractory B-cell Lymphoma are expected by the end of 2022.

Caribou Biosciences: Potential To Change CAR-T Landscape

Caribou Biosciences Inc (NASDAQ: CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).  Following a single dose at the initial dose level of 40 million CAR.

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences, Inc. (NASDAQ: CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology Association 2022 Hybrid Congress. A 100% complete response rate (6 of 6 patients) was.

What's Going On With Caribou Biosciences Shares Today?

-- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- First patient treated in the ANTLER trial remained in CR at 12 months  --

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

-- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients -- -- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients --

Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022

Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the presentations the companies will be making at next month's European Hematology Association meeting.

Caribou Charges Ahead on Study Results

-- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances -- -- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances --

Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors

-- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy candidate, in patients with r/r B-NHL -- -- Submission of IND application planned in H2 2022 for CB-011, Caribou's second allogeneic cell therapy candidate, for evaluation in patients with r/r multiple myeloma --

Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates

BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the following upcoming investor conference in May:

Caribou Biosciences to Present at Upcoming Investor Conference

-- Data highlight the mechanism underlying the superior specificity of Caribou's chRDNA genome-editing technology in primary human T cells -- -- Data highlight the mechanism underlying the superior specificity of Caribou's chRDNA genome-editing technology in primary human T cells --

Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)

-- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r/r B-NHL -- -- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r/r B-NHL --

Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 Hybrid Congress

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked  to blunt both T- and NK-mediated immune cell rejection,  enabling more durable antitumor activity -- -- Data support an expected Investigational New Drug (IND) application submission in 2022 for  CB-011, Caribou's second allogeneic cell therapy product candidate --

Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate  for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate for patients with r/r multiple myeloma --

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma (r/r MM), will be presented as a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022 in New Orleans.

Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will present a company overview at the following upcoming investor conferences in March:

Caribou Biosciences to Present at Upcoming Investor Conferences

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17th, at 2:20 pm ET.

News for Caribou Biosciences Stock (CRBU)